Research article

Pick analysis

History arrow_forward
Misty mountains rise above a calm lake at dawn
Research brief

Sep 29, 2026 Morning

02:20 PM UTC
N/A N/A N/A

Final allocation: Keep cash (N/A)

After the stock-selection N/A, a separate review compared S&P 500 exposure (VOO; SPY is an equivalent market proxy) with Robinhood Gold cash over 28 days. Gold cash APY: 3.6%, checked 2026-09-29T16:00:01.867617+00:00; matched cash return: 0.2717%. Current base APY held constant; existing Gold subscription; pre-tax eligible settled cash, no margin debit or promotional boost.

Estimated net index return: +0.2000%; forecast uncertainty: 0.5000 percentage points; conservative excess over cash: -0.5717%.

Keep eligible settled cash earning the existing Robinhood Gold rate, without placing an order. The official Robinhood rate page states 3.6% base APY as of September 17, 2026, subject to change; the supplied official snapshot was checked at 2026-09-29T16:00:01.867617+00:00. Holding that APY constant for exactly 28 eligible days gives 100*((1+3.6/100)^(28/365)-1) = +0.2716779741% pre-tax. Existing Gold membership is assumed and its fee is sunk; there is no margin debit or promotional boost. The fresh analyst VOO buy-and-hold estimate is +0.20% net, already 0.0716779741 percentage point below cash, and -0.30% after the positive 0.50-point forecast deduction, 0.5716779741 point below cash. With zero in-window dividend and 0.10% execution friction, VOO would need more than +0.8716779741% price appreciation to clear cash after that deduction. The strongest contrary evidence is improving S&P 500 earnings estimates, positive longer-horizon analyst targets, and VOO's position above its 50-session average; none establishes that particular 28-day threshold. Separately, the supplied portfolio rule says existing public index exposure makes another public VOO lot unavailable; the enumerated positions do not identify that index lot, so no ticker is invented. Listed Technology plus Industrials positions already account for about 11.4021 of 16.4278 active slots, or 69.4%, adding concentration context rather than treating stock N/A as bearish. Finally, the 12:00 VOO last trade is not an executable ask and no fresh bid/ask-anchored entry or valid authored-stop/profit-barrier probability plan is available. The 60-minute-average stop with 120-minute confirmation and the separate 15% hard loss with 10-minute confirmation can execute beyond their thresholds; a VOO policy-executed, cash-through-horizon return therefore cannot be certified to beat Gold. This is an independent cash allocation decision; the complete 13-name stock audit remains unchanged. Surf Google search presented a human challenge, so it was not resumed; direct issuer, regulator, market and data-source pages supplied the material evidence.

Separate 28-calendar-day allocation estimate for 2026-09-29 through 2026-10-27, not a revision of the audited stock N/A. Current VOO quote refreshed at 12:00 ET is $701.50 (versus the saved report's earlier $702.02 at 11:38 ET); SPY is $763.16 at 12:00 ET. These are last-trade snapshots, not executable bid/ask offers. VOO is below its completed 20-session SMA $702.163 and 11:55 completed-bar session VWAP $703.2462, but above its completed 50-session SMA $698.8989; the September 28 completed session fell 0.76%. Analyst 28-day buy-and-hold forecast: +0.30% price return, 0.00% dividend, minus 0.10% assumed round-trip spread/impact and sale friction = +0.20% net. The price drift and friction are judgmental estimates, not market-implied or empirically calibrated forecasts. Vanguard's 2026 distribution schedule gives VOO ex-dates September 28 and December 21, bracketing this holding window, so no in-window dividend is counted. The VOO prospectus lists a 0.03% annual expense ratio already reflected in traded price/NAV; it is not subtracted again. Causal upside support: FactSet found Q3 bottom-up EPS estimates rose 1.2% from June 30 to August 31, and FactSet's September 28 analysis reports a 20.4% aggregate analyst target gap over 12 months; that longer-horizon target is contrary bullish evidence, not scaled to 28 days. Counterweight: the Federal Reserve raised its target range to 3.75%-4.00% on September 16, the NYSE's 09:00 ET update indicated a 5.23% 10-year yield (not a 12:00 synchronized yield), and the VOO quote profile reports P/E about 24.68 with no forward-P/E field. Higher discount rates and a noncheap multiple can offset earnings improvement within four weeks. Explicit forecast sensitivity: a rate/valuation repricing that changes the assumed price return from +0.30% to -0.20% changes net buy-and-hold to -0.30%. The 0.50-percentage-point positive uncertainty deduction is that evidence-motivated adverse price-drift revision, applied once, not ATR/VIX/one-sigma or a second charge for an already modeled downside outcome; it is an uncalibrated analyst stress, not a worst-case bound. Thus the adjusted index estimate is -0.30%. A stronger +1.00% price outcome would instead yield +0.90% net and +0.40% after the same deduction, illustrating that the forecast can change sign. SPY is the S&P 500 exposure comparator, not an additional hurdle; the saved stock report's earlier +0.20% net SPY estimate is also judgmental and is not extrapolated.

The following stock-selection report is retained as the prior research record.

Summary

  • Stock decision: N/A for a new immediate-buy lot through the 28-calendar-day horizon ending October 27, 2026. The certified 13-symbol audit contains eight fully modeled actionable candidates, none with positive modeled net absolute return after its uncertainty deduction, and five evidence-specific hard rejections. This is not a broad-bear-market claim or a confidence-level veto. The decider supplied no separate market_regime_evidence field; its documented non-crash basis is that SPY remained above its completed 50-day average at the decision snapshot. finance.yahooYahoo Finance: State Street SPDR S&P 500 ETF TrustYahoo Finance quote pageVisit original website ↗
  • Closest stock case: Iovance Biotherapeutics (IOVA) had a genuinely new September 29 revenue-guide increase and an intraday post-gap base, yet the decider's +4.1945% modeled policy return minus 4.50 percentage points of forecast uncertainty was −0.3055%. Its $15.50 four-week T1 is not the $16.648 full-position profit barrier. stocktitan.nesourceVisit original website ↗finance.yahooYahoo Finance: Iovance Biotherapeutics, Inc.Yahoo Finance quote pageVisit original website ↗
  • Separate allocation choice: assuming existing Robinhood Gold membership and eligible settled cash, hold the available slot in Gold cash rather than VOO over the same 28 days. The allocation review estimated +0.27168% cash interest at an unchanged 3.6% APY, versus +0.20% net VOO before and −0.30% after its 0.50-point forecast-uncertainty allowance. This conditional allocation choice does not reverse the stock N/A. robinhoodsourceVisit original website ↗finance.yahooYahoo Finance: Vanguard S&P 500 ETFYahoo Finance quote pageVisit original website ↗

Why Now

Iovance's first public disclosure of the new economics was its September 29, 07:00 ET release: 2026 revenue guidance rose from $350–370 million to $410–420 million. The midpoint rose $55 million, about 15% (calculation); management cited Amtagvi and Proleukin demand. However, the August 6 disclosure had already signaled a review of the old range, so only the quantified new guidance is fresh, not the prospect of an update itself. stocktitan.nesourceVisit original website ↗sec.govsourceVisit original website ↗ The earlier Q2 release reported $99.3 million revenue, 56% gross margin and about $304 million cash at June; management projected runway into the second half of 2028. These observations support operating and funding resilience, but do not establish how much of the guide lift was absent from the opening price. sec.govsourceVisit original website ↗

At the final 11:31 ET stock-data snapshot, IOVA was $14.065, versus the September 28 $10.99 close: +27.98% (calculation). Partial-session volume was 31.3 million shares versus a 14.0 million completed-session average, and displayed short float was 20.57%; the stock was near its $14.11 reported event/52-week high. The price and volume confirm attention, not additional future return. A completed 30-minute sequence above the opening-inclusive $13.573 event VWAP satisfied the mandatory post-gap acceptance test; its feed is not an exchange-certified auction. finance.yahooYahoo Finance: Iovance Biotherapeutics, Inc.Yahoo Finance quote pageVisit original website ↗ A same-day retail post only repeated the guidance and had one vote when indexed. Sentiment assessment (analyst inference): that is too thin to validate independent demand or calibrate exit odds. redditsourceVisit original website ↗

Business And Market Context

Amtagvi/Proleukin demand is the issuer's stated commercial driver for the higher guide; this is near-window revenue information, unlike longer-dated contract or synergy headlines elsewhere in the slate. stocktitan.nesourceVisit original website ↗ir.coherentsourceVisit original website ↗bluevinesourceVisit original website ↗ Market leadership was selective rather than broad: at 10:25 ET, three of seven sampled sector SPDRs were positive, while XLV was −1.13%, SOXX +2.11%, and at 10:26 ET RSP and IWM were negative. These are an ETF sample—not exchange-wide breadth—and are earlier than the 11:31 IOVA snapshot, so no matched-timestamp sector alpha is claimed. finance.yahoYahoo Finance: State Street Technology Select Sector SPDR ETFYahoo Finance quote pageVisit original website ↗finance.yahoYahoo Finance: State Street Industrial Select Sector SPDR ETFYahoo Finance quote pageVisit original website ↗finance.yahoYahoo Finance: State Street Utilities Select Sector SPDR ETFYahoo Finance quote pageVisit original website ↗finance.yahoYahoo Finance: State Street Financial Select Sector SPDR ETFYahoo Finance quote pageVisit original website ↗finance.yahoYahoo Finance: State Street Health Care Select Sector SPDR ETFYahoo Finance quote pageVisit original website ↗finance.yahoYahoo Finance: State Street Communication Services Select Sector SPDR ETFYahoo Finance quote pageVisit original website ↗finance.yahoYahoo Finance: State Street Materials Select Sector SPDR ETFYahoo Finance quote pageVisit original website ↗finance.yahoYahoo Finance: iShares Semiconductor ETFYahoo Finance quote pageVisit original website ↗finance.yahoYahoo Finance: Invesco S&P 500 Equal Weight ETFYahoo Finance quote pageVisit original website ↗finance.yahoYahoo Finance: iShares Russell 2000 ETFYahoo Finance quote pageVisit original website ↗ The NYSE's 09:00 ET note put the 10-year Treasury near 5.23%; that was a preopen indication, not a synchronized 11:31 rate. e.nysesourceVisit original website ↗

SPY was $762.85 at 11:29 ET, below its completed 20-day average of $763.93 but above its 50-day average of $760.39. Analyst interpretation: this permits selective longs but does not certify a crash or bear regime; narrow breadth and rate pressure warrant a modest, uncertain index forecast. finance.yahooYahoo Finance: State Street SPDR S&P 500 ETF TrustYahoo Finance quote pageVisit original website ↗e.nysesourceVisit original website ↗ The decider estimated SPY's matched September 29–October 27 net buy-and-hold return at +0.20%: assumed +0.30% price drift, no qualifying ex-dividend inside the window, and −0.10% estimated trading friction. State Street's September 18 and December 18 ex-dates bracket the interval; the drift and friction are analyst assumptions, not source forecasts or a quoted spread. ssgasourceVisit original website ↗finance.yahooYahoo Finance: State Street SPDR S&P 500 ETF TrustYahoo Finance quote pageVisit original website ↗

Factor Stack

Factor Evidence and interpretation
Catalyst and growth The newly quantified $55 million guidance-midpoint uplift is the strongest fresh operating delta in the reviewed slate; the earlier review notice reduces surprise. Analyst inference: some further repricing is plausible, but the +27.98% opening-to-snapshot move already discounts a material amount. stocktitan.nesourceVisit original website ↗sec.govsourceVisit original website ↗finance.yahooYahoo Finance: Iovance Biotherapeutics, Inc.Yahoo Finance quote pageVisit original website ↗
Profitability and funding Q2's reported 56% gross margin and roughly $304 million June cash, with management's runway statement, mitigate immediate solvency concern; they do not turn the stock into a low-risk 28-day trade. sec.govsourceVisit original website ↗
Valuation and revisions The supplied evidence establishes the company's guide change, but not a contemporaneous, quantified analyst-estimate revision or defensible near-window valuation multiple. Limitation: neither is used to manufacture a higher target. stocktitan.nesourceVisit original website ↗
Momentum and entry The $14.065 11:31 ET quote was near $14.11 resistance after a large gap; the completed above-VWAP base is constructive, but a move to the actual $16.648 exit still requires material further travel. finance.yahooYahoo Finance: Iovance Biotherapeutics, Inc.Yahoo Finance quote pageVisit original website ↗
Social/expert confirmation One low-engagement retail recap is not independent commercial evidence. No policy-exit reference sample was supplied; probabilities below are uncalibrated decider estimates. redditsourceVisit original website ↗

Investment Thesis And Scenario Arithmetic

The best case is real, but not strong enough at the frozen price. The decider set IOVA's research entry at $14.065 (11:31 ET), authored stop at $13.10, conditional actual stop-exit estimate at $12.40, first resistance at $14.11, and an evidence-anchored 28-day T1 at $15.50. The T1 was an analyst halfway extension toward a $17.05 measured move from the prior $11.17 high and current $14.11 high; it was not a provider target. The stop lay below the $13.195 reaction low and about 1.58 pre-event ATR from entry. finance.yahooYahoo Finance: Iovance Biotherapeutics, Inc.Yahoo Finance quote pageVisit original website ↗

The full-position profit exit is not T1. The exact policy sets its return to 1.8 × (15.50/14.065 − 1) × 100 = +18.3647%, implying a $16.648 barrier. The decider assigned mutually exclusive 40% barrier exit / 30% confirmed stop exit / 30% October 27 time exit, with +2% conditional time-exit return and 0.20% friction. These are uncalibrated analyst probability and return assumptions, not reported company facts or historical frequencies; the 40% entails both clearing $14.11 and then reaching $16.648 before either other exit. finance.yahooYahoo Finance: Iovance Biotherapeutics, Inc.Yahoo Finance quote pageVisit original website ↗

Calculation from the frozen assumptions: 0.40 × 18.3647% + 0.30 × (12.40/14.065 − 1) × 100 + 0.30 × 2.0% − 0.20% = +4.1945% expected net policy return. Against the decider's +0.20% net SPY estimate, raw modeled excess is +3.9945 percentage points. Deducting the decider's evidence-judgment 4.50-point uncertainty allowance once yields −0.3055% adjusted absolute return and −0.5055-point adjusted excess. The former—not lack of SPY outperformance or a confidence threshold—fails the required immediate-buy gate. A matched policy-exit sample with dates, size and exact exit definitions was unavailable, so these odds are not statistically calibrated. finance.yahooYahoo Finance: Iovance Biotherapeutics, Inc.Yahoo Finance quote pageVisit original website ↗globenewswirsourceVisit original website ↗

The decider's coherent adverse challenge kept entry, stop and T1 fixed but changed the outcome odds to 31%/36%/33%, the time-exit return to 0%, and conditional stop exit to $12.00, leaving SPY unchanged. It produced +0.2076% net and a 3.9869-point minimum stress-covering uncertainty; the declared 4.50 points covers that deterioration once. Analyst interpretation: the tiny base-case adjusted deficit is highly quote- and assumption-sensitive, but a stress-consistent near miss is still not a positive supported forecast. finance.yahooYahoo Finance: Iovance Biotherapeutics, Inc.Yahoo Finance quote pageVisit original website ↗globenewswirsourceVisit original website ↗

Risks And Thesis Breakers

The strongest counterargument to N/A is the newly quantified guide increase, high turnover and a completed above-event-VWAP base; short interest could amplify a follow-through move. Yet the same +27.98% repricing, proximity to the event high, unverified analyst estimate response, and distance to the $16.648 actual exit leave too little margin after model uncertainty. This is an analyst judgment based on the cited tape and release, not a claim that the company has exhausted all upside. stocktitan.nesourceVisit original website ↗finance.yahooYahoo Finance: Iovance Biotherapeutics, Inc.Yahoo Finance quote pageVisit original website ↗

If reconsidered, the $13.10 authored stop is a monitoring threshold, not a guaranteed fill: the policy requires the trailing 60-minute average below it for 120 minutes. The separate 15% hard-loss condition requires 10 minutes of confirmation. Gaps and delayed confirmations could put execution below either threshold; the decider's $12.40 conditional stop-exit estimate explicitly allows this and remains uncertain. The 0.20% total friction includes 0.10% adverse exit slippage; it is not added twice. Proceeds after any early stock exit sit in cash until October 27, whereas SPY is held through the horizon. finance.yahooYahoo Finance: Iovance Biotherapeutics, Inc.Yahoo Finance quote pageVisit original website ↗

Concrete monitoring/invalidation conditions: refresh the stock-data quote and the completed opening-inclusive event VWAP/base before any new decision. A break of the $13.195 reaction low or loss of the $13.573 event-VWAP area would undermine the present support thesis; a sustained move above $14.11 would only clear first resistance, not validate the $16.648 barrier probability. New estimate revisions, clinical timing, or a later lower entry require a fully synchronized new 28-day scenario, SPY comparison and stress deduction—not reuse of this near-zero case. The Q3 report was expected in early November, outside this horizon; the specific Q4 clinical calendar remained unresolved. finance.yahooYahoo Finance: Iovance Biotherapeutics, Inc.Yahoo Finance quote pageVisit original website ↗sec.govsourceVisit original website ↗

Investment Recommendation And Opportunity Cost

Do not initiate a new stock lot at the frozen quotes. This follows a complete non-crash recovery: the original 19-name discovery slate yielded ten full deep dives, then exactly one additional 503-name S&P 500 screen and distinct mover, earnings/guidance and sector/theme searches; 13 symbols reached the final structured review. Some newly found ideas were not assigned fabricated policy odds merely to fill the audit. The candidate-level evidence and unchanged probabilities, benchmarks and uncertainty assumptions are preserved in the frontmatter. finance.yahoYahoo Finance screener: sp500Universe=sp500Visit original website ↗finance.yahoYahoo Finance: CarMax, Inc.Yahoo Finance quote pageVisit original website ↗finance.yahoYahoo Finance: Summit Therapeutics Inc.Yahoo Finance quote pageVisit original website ↗finance.yahoYahoo Finance: Volato Group, Inc.Yahoo Finance quote pageVisit original website ↗

Next-available-candidate comparison: HOOD was the best remaining fully modeled alternative. At its $115.02, 11:29 ET snapshot, the decider used $105 authored stop, $100 conditional exit, $126.74 T1 and $136.116 actual barrier. Its assumed 26%/30%/44% exits produced +1.1411% net, +0.9411-point excess to SPY, but −2.3589% adjusted absolute after 3.50-point uncertainty. The September 10 deposit data were older, and price remained below about $117.20 session VWAP after four declining sessions; its stress required a 2.9854-point floor, covered by the 3.50 points. Cleaner alternative status cannot turn its negative adjusted absolute return into a buy. finance.yahoYahoo Finance: Robinhood Markets, Inc.Yahoo Finance quote pageVisit original website ↗investors.rosourceVisit original website ↗ APP and COHR also had positive raw net models but negative adjusted absolutes (−1.999% and −2.6089%, respectively); other actionable rows were weaker, while the five hard-rejected rows retain their distinct documented reasons rather than hypothetical returns. finance.yahoYahoo Finance: AppLovin CorporationYahoo Finance quote pageVisit original website ↗finance.yahoYahoo Finance: Kodiak Sciences Inc.Yahoo Finance quote pageVisit original website ↗

Allocation, separately: for an account already paying for Gold with eligible settled cash, the review chose Robinhood Gold cash over VOO through October 27. Robinhood's dedicated page posted 3.6% APY as of September 17, subject to change. At an unchanged APY and 28 eligible days, (1.036)^(28/365) − 1 = +0.27168%, about $27.17 per $10,000 before tax. A stale overview page still showed 3.35% dated February 11; the newer dedicated rate was used. The $5 monthly Gold fee is treated as an existing account cost, not silently waived for a new member. robinhoodsourceVisit original website ↗robinhoodsourceVisit original website ↗

VOO was $702.02 at 11:38 ET, below its completed 20-day average and session VWAP but above its 50-day average. The allocation review assumed, rather than observed, the same +0.30% 28-day index price drift, 0% in-window dividend, and 0.10% round-trip execution friction for +0.20% net; a 0.50-point uncalibrated forecast sensitivity yielded −0.30% adjusted. Vanguard's September 28 ex-date preceded entry and December 21 ex-date followed the horizon; its 0.03% annual fund expense is already reflected in the price/NAV path and is not deducted twice. The 0.10% is an analyst spread/impact and sale-fee allowance, not a live quoted spread or broker commission. finance.yahooYahoo Finance: Vanguard S&P 500 ETFYahoo Finance quote pageVisit original website ↗advisors.vansourceVisit original website ↗sec.govsourceVisit original website ↗robinhoodsourceVisit original website ↗

Calculation: Gold exceeds the base VOO estimate by 0.07168 point, and the uncertainty-adjusted estimate by 0.57168 point. VOO would need more than 0.37168% price appreciation to exceed cash after assumed trading friction, or 0.87168% under the stated 0.50-point uncertainty allowance. The cash choice does not depend on that allowance. It is conditional on existing Gold membership, settled-cash eligibility, unchanged APY and 28 interest-earning days; absent Gold, an incremental $5 fee, rate changes, or different executable VOO spreads require a fresh account-specific comparison. The VOO quote is a snapshot, not a future fill or guaranteed return. robinhoodsourceVisit original website ↗sec.govsourceVisit original website ↗finance.yahooYahoo Finance: Vanguard S&P 500 ETFYahoo Finance quote pageVisit original website ↗

References

Disclaimer: This is not financial advice. All investments carry risk. Please do your own research and consult with a financial advisor before making investment decisions.